Le Lézard
Classified in: Health
Subjects: PDT, TDS, FDA

OsteoRemedies® Announces the First FDA Cleared Dual-Antibiotic Spacer and Bone Cement with Gentamicin and Vancomycin


MEMPHIS, Tenn., Nov. 1, 2018 /PRNewswire/ -- OsteoRemedies®, LLC, a company focused on providing simple solutions to complex disorders, is pleased to announce the launch of the REMEDY SPECTRUMtm? GV Hip Spacer System and SPECTRUMtm? GV Bone Cement.  Building on its portfolio consisting of the only pre-made modular spacer system with Gentamicin for Hip, Knee and Shoulders, the REMEDY SPECTRUMtm? GV Hip System will provide surgeons with the first ever broad-spectrum treatment option with both Gentamicin and Vancomycin.

"We are very proud to have the first FDA cleared dual-antibiotic spacer system and bone cement offering," stated Chris Hughes, President and Chief Executive Officer of OsteoRemedies®.  "Since we started the company in 2013, our commitment to the growing problem of treating joint infections has been our mission.  The amount of science, testing and clinical data supporting this launch is unparalleled in our space.  The addition of the SPECTRUMtm? GV portfolio, further enhances our vision for providing simple solutions for complex disorders for revision infection remedies and achieving a market leadership position in our niche."

The launch of the SPECTRUMtm? GV system will begin November 1- 4 at the American Academy of Hip and Knee Surgeons (AAHKS) in Dallas, Texas where OsteoRemedies® will be exhibiting at Booth # 308.  In addition to the introduction of SPECTRUMtm, OsteoRemedies® will also be showcasing the newly launched REMEDY® Acetabular Cup Spacer, which in conjunction with the REMEDY® Hip System, provides the only Pre-formed all PMMA hip spacer option on the market. The existing portfolio will also be displayed, including the REMEDY® Modular Hip, Knee and Shoulder Spacer, OSTEOBOOST®? RBK and FLORASEAL®? Microbial Sealant along with UNITE® Antibiotic Bone Cement.

About OsteoRemedies®, LLC
OsteoRemedies provides simple solutions to complex musculoskeletal disorders.  Their first introduction was the REMEDY® Spacer System. This was the first available modular system for hip, knee and shoulder two-stage infection revision arthroplasty.  The REMEDY® Spacer System and REMEDY SPECTRUMtm? GV Hip Spacers are indicated for temporary use (maximum 180 days) as an adjunct to total joint replacement in skeletally mature patients undergoing a two-stage procedure due to a septic process and where gentamicin or gentamicin and vancomycin are the most appropriate antibiotics based on the susceptibility pattern of the infecting micro-organisms.  SPECTRUMtm GV Bone Cement is indicated for use with the REMEDY SPECTRUMtm GV Hip Spacer System.  Other product offerings include OSTEOBOOST®? RBK and FLORASEAL®? Microbial Sealant and UNITE®? AB Bone Cement.

The Company's web site for news releases and other information is http://www.osteoremedies.com.

Contact 
Eric Stookey
[email protected]

 

SOURCE OsteoRemedies


These press releases may also interest you

at 04:00
OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announces to be the official sponsor of May Measurement Month (MMM,) a global campaign to raise awareness of blood pressure screening and promote hypertension prevention, detection,...

at 02:48
Today, RaySearch Laboratories AB (publ)  publishes its Annual Report for the financial year 2023. The report is held available on RaySearch's website, under the section Investors.  This information is information that RaySearch Larboratiories AB...

at 02:43
Shareholders of Zinzino AB (publ) are hereby invited to the annual general meeting on Monday, May 27, 2024, at 1:30 PM at the company's premises at Hulda Mellgrens gata 5 in Gothenburg. Registration begins at 1:15 PM. The company aims to webcast the...

at 02:41
Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2023. The annual report is now available on the company's website. "Implantica had a very...

at 02:08
Revenue amounted to ?498.8m (?419.3m), an increase of 18.9% with an organic growth of 14.2%.Operating profit (EBIT) was ?19.0m (?10.7m), an increase of 78.0%, representing an operating margin of 3.8% (2.6%).Net profit amounted to ?6.5m (?2.1m), which...

at 02:00
Amwins Global Risks is delighted to announce Classic Cars and Cotswolds, an auction to raise money for the Matthew Wilson Multiple Myeloma Fund at Blood Cancer UK. The online auction opens today and features Ferraris, Aston Martins, a Rolls Royce, a...



News published on and distributed by: